Abstract
This is a Phase II pilot study to determine the efficacy of three fixed dose (1 x 108/kg)
infusions of ex-vivo expanded human leukocyte antigen (HLA)-haploidentical donor natural
killer (NK) cells (haploNK) in children and young adults with high risk acute myeloid
leukemia (AML) undergoing HLA-haploidentical hematopoietic cell transplant (haploHCT) with a
busulfan and cyclophosphamide-based myeloablative conditioning regimen and post-transplant
cyclophosphamide (PTCy) for graft versus host disease (GVHD) prophylaxis. The investigators
will also demonstrate the feasibility of performing this trial in a multi-center study.
The investigators hypothesize that the infusion of haploNK in this setting will facilitate
immune reconstitution and decrease relapse rates and infectious complications without
increasing GVHD, resulting in improved survival as compared to recent historical cohorts of
haploHCT without NK cell infusion.
